Exons News and Research RSS Feed - Exons News and Research

Baylor-led researchers identify gene linked to familial glioma

Baylor-led researchers identify gene linked to familial glioma

An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease. [More]
Researchers show that iPS cells can be used to edit genetic mutations that cause DMD

Researchers show that iPS cells can be used to edit genetic mutations that cause DMD

Researchers at the Center for iPS Cell Research and Application, Kyoto University, show that induced pluripotent stem (iPS) cells can be used to correct genetic mutations that cause Duchenne muscular dystrophy (DMD). [More]
OGT workshop to focus on using latest genomic technologies for accelerating cancer research

OGT workshop to focus on using latest genomic technologies for accelerating cancer research

Oxford Gene Technology, The Molecular Genetics Company, will present a workshop titled ‘An Integrated Genomic Approach to Tumor Profiling’ at the Association for Molecular Pathology annual meeting on the 12-15th November at National Harbor, MD. [More]
Four UCLA researchers receive NIH Director's New Innovator Award

Four UCLA researchers receive NIH Director's New Innovator Award

Four scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received a National Institutes of Health Director's New Innovator Award that will forward revolutionary stem cell and neuro-science in medicine. [More]
OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N. [More]
Changes in ADNP gene may provide further insight into causes of autism

Changes in ADNP gene may provide further insight into causes of autism

A new study from Bradley Hospital has identified a genetic change in a recently identified autism-associated gene, which may provide further insight into the causes of autism. The study, now published online in the Journal of Medical Genetics, presents findings that likely represent a definitive clinical marker for some patients' developmental disabilities. [More]
BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

Among men with prostate cancer detected on screening, survival among those with a mutation in the BRCA2 gene is much poorer than in those without such a mutation, researchers report. [More]
Isoform: New protein offers novel therapeutic approach for patients with DMD

Isoform: New protein offers novel therapeutic approach for patients with DMD

Scientists have discovered a new form of dystrophin, a protein critical to normal muscle function, and identified the genetic mechanism responsible for its production. [More]
Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 (NRG1) is a pleiotropic factor characterized by the existence of numerous isoforms arising from alternative splicing of exons that confer to the protein deeply different characteristics. [More]
Exome sequencing improves diagnosis of mitochondrial disease

Exome sequencing improves diagnosis of mitochondrial disease

Use of exome sequencing improved the ability to identify the underlying gene mutations in patients with biochemically defined defects affecting multiple mitochondrial respiratory chain complexes (enzymes that are involved in basic energy production), according to a study in the July 2 issue of JAMA. [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
Researchers identify heart-specific form of protein that protects against irregular heartbeats

Researchers identify heart-specific form of protein that protects against irregular heartbeats

Researchers at the Cedars-Sinai Heart Institute have identified a heart-specific form of a protein, BIN1, responsible for sculpting tiny folds in pockets that are present on the surface of heart muscle cells. [More]
Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). [More]
Researchers demonstrate accurate identification of amino acids

Researchers demonstrate accurate identification of amino acids

Some three billion base pairs make up the human genome-the floor plan of life. In 2003, the Human Genome Project announced the successful decryption of this code, a tour de force that continues to supply a stream of insights relevant to human health and disease. [More]
Study highlights the importance of personalized medicine for treating cancer

Study highlights the importance of personalized medicine for treating cancer

If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient's cancer treatment on commonly disrupted genes and pathways. [More]
Small non-coding RNAs can help predict individuals with breast cancer

Small non-coding RNAs can help predict individuals with breast cancer

Small non-coding RNAs can be used to predict if individuals have breast cancer conclude researchers who contribute to The Cancer Genome Atlas project. The results, which are published in EMBO reports, indicate that differences in the levels of specific types of non-coding RNAs can be used to distinguish between cancerous and non-cancerous tissues. These RNAs can also be used to classify cancer patients into subgroups of individuals that have different survival outcomes. [More]
Novel HER2 mutation identified in familial lung adenocarcinomas

Novel HER2 mutation identified in familial lung adenocarcinomas

Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. [More]
European Commission approves update of Erbitux  to treat patients with RAS wild-type mCRC

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]